[Skip to Content]
[Skip to Content Landing]
Views 110
Citations 0
Comment & Response
September 11, 2019

Lymphatic and Hematogenous Dissemination in Patients With Primary Cutaneous Melanoma—Reply

Author Affiliations
  • 1Department of Dermatology, Instituto Valenciano de Oncología, València, Spain
  • 2School of Medicine, Universidad Católica de Valencia San Vicente Mártir, València, Spain
  • 3Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany
JAMA Dermatol. Published online September 11, 2019. doi:10.1001/jamadermatol.2019.2329

In Reply We are grateful to Adler and colleagues for their interest in our published study.1 We do agree that our results do not rule out the role of tumor mutational profile in the lymphatic spread of melanoma. On the contrary, our data support their results that indicate the prognostic value of BRAF mutation for lymphatic spread of melanomas. In our series, BRAF mutation (hazard ratio [HR], 1.9; 95% CI, 1.2-3.2; P = .005) was associated with an increased risk of lymphatic spread in univariate analysis (see eTable 2 in the Supplement of the article)1; thus, the effect of the association is in the same direction as in the study by Adler et al.2 However, the association did not remain statistically significant after multivariate analysis. The association between BRAF and TERT promoter mutations and hematogenous spread remained statistically significant even after multivariate analysis, indicating that those mutations are greater risk factors for hematogenous spread than for lymphatic spread.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words